Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Post-Treatment Lyme Disease: early-phase trial registry

5 of 5 indexed Post-Treatment Lyme Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 5 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Post-Treatment Lyme Disease: 5 US clinical trials tracked, 5 recruiting.

Post-Treatment Lyme Disease is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Children's National Research Institute, running 2 of these trials.

Enrollment posture brief

Registry condition post-treatment-lyme-disease

OPEN 5 | RECR 100% | LATE 0 | EARLY 1 | RANK #3391 | SPON 2

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Post-Treatment Lyme Dise (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Post-Treatment Lyme Disease

Post-Treatment Lyme Disease lists 5 open slots (100% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Post-Treatment Lyme Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Post-Treatment Lyme Disease is recruiting above its size-band peers.

    5 of 5 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Post-Treatment Lyme Disease research.

    Children's National Research Institute accounts for 2 of 5 trials (40%). 3 distinct sponsors appear on at least one study for this condition label.

  3. Most Post-Treatment Lyme Disease trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Post-Treatment Lyme Disease splits between interventional and observational designs.

    3 interventional and 2 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Post-Treatment Lyme Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Dextrose 5% (D5W) Drug
1 trials
Ceftriaxone (Rocephin®) Drug
1 trials
Quantitative surveys and qualitative interview Other
1 trials
taVNS Device
1 trials
Cognitive training Behavioral
1 trials
Neurodevelopmental assessments and follow-up Other
1 trials
Transcranial Direct Current Stimulation (tDCS) Device
1 trials

US sites by state

Facility locations filed on Post-Treatment Lyme Disease trials. A trial with sites in several states counts in each.

New York 3 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Post-Treatment Lyme Disease page

5 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Post-Treatment Lyme Disease condition card totals 5 registered trials; most-linked intervention Dextrose 5% (D5W); top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.